Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
University of Copenhagen |
---|---|
Information provided by: | University of Copenhagen |
ClinicalTrials.gov Identifier: | NCT00259532 |
The purpose of this project is to evaluate and compare three new methods for diagnosis, staging, operability evaluation and treatment control of pancreas cancer. The investigators use contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin, which triggers the enzyme production of pancreas. The hormones induce an increased metabolism and thus an increased blood flow through healthy pancreas tissue, however, not in tumor tissue. The investigators hope to be able to use this effect diagnostically. The patients included will also have a 64-slice-CT in order to evaluate, if an increased diagnostic safety can be reached compared to an older CT scanning method. All patients will also be examined for the tumor marker CA 19-9. Further, the investigators will examine if contrast-enhanced ultrasound can contribute with information in treatment control after either surgery or medical treatment.
Condition | Intervention |
---|---|
Pancreas Cancer |
Procedure: Ultrasound and contrast agent |
Study Type: | Interventional |
Study Design: | Diagnostic, Non-Randomized, Single Blind, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | Ultrasound With Contrast Agent, 64-Slice-CT and Tumormarkers for Diagnosing, Evaluation of Operability and Treatment Control of Pancreas Cancer |
Estimated Enrollment: | 80 |
Study Start Date: | February 2005 |
Estimated Study Completion Date: | January 2009 |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria: - suspicion of cancer of the pancreas
Contact: Hanne S Grossjohann, MD | +45 35453419 | hannesonder@dadlnet.dk |
Denmark | |
Copenhagen University Hospital | Recruiting |
Copenhagen, Denmark, 2100 | |
Contact: Hanne S Grossjohann, MD +45 35453419 hannesonder@dadlnet.dk | |
Principal Investigator: Hanne S Grossjohann, MD |
Principal Investigator: | Michael B Nielsen, DMSc | Department of Radiology, Section of Ultrasound |
Study ID Numbers: | (KF) 01 268342 |
Study First Received: | November 25, 2005 |
Last Updated: | February 25, 2009 |
ClinicalTrials.gov Identifier: | NCT00259532 History of Changes |
Health Authority: | Denmark: Ethics Committee |
Secretin Digestive System Diseases Digestive System Neoplasms Cholecystokinin Pancreatic Neoplasms Endocrine System Diseases |
Pancreatic Diseases Gastrointestinal Neoplasms Endocrinopathy Pancrelipase Hormones Endocrine Gland Neoplasms |
Neoplasms Digestive System Diseases Neoplasms by Site Digestive System Neoplasms Therapeutic Uses Pancreatic Neoplasms |
Gastrointestinal Agents Endocrine System Diseases Pancreatic Diseases Pancrelipase Pharmacologic Actions Endocrine Gland Neoplasms |